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Abstract
Background: during adulthood, most studies have reported that oral contraceptive (OC) pills had
neutral, or possibly beneficial effect on bone health. We proposed this study of pre and post
menopausal women assessing BMD, bone biochemical markers and physical performance among
OC past users and comparable women who have never use Ocs.
Methods:  A cross-sectional study comparing the bone density, bone biochemical markers
(osteocalcin, CTX) and three measures to assess physical performance: timed get-up-and-go test
"TGUG", five-times-sit-to-stand test "5 TSTS" and 8-feet speed walk "8 FSW" of users and never
users OC. We were recruited 210 women who used OC for at least 2 years with that of 200
nonusers was carried out in pre and postmenopausal women (24-86 years).
Results: when analysing the whole population, BMD and biochemical markers values were similar
for Ocs past users and control subjects. However when analysing the subgroup of premenopausal
women, there was a statistically significant difference between users and never-users in osteocalcin
(15,5 ± 7 ng/ml vs 21,6 ± 9 ng/ml; p = 0,003) and CTX (0,30 ± 0,1 ng/ml vs 0,41 ± 0,2 ng/ml; p =
0,025). This difference persisted after adjustment for age, BMI, age at menarche and number of
pregnancies. In contrast, in post menopausal women, there was no difference in bone biochemical
markers between OC users and the control. On the other hand OC past users had a significant
greater performance than did the never users group. And when analysing the physical performance
tests by quartile OC duration we found a significant negative association between the three tests
and the use of OC more than 10 years.
Conclusion: the funding show no evidence of a significant difference in BMD between Ocs users
and never user control groups, a decrease in bone turn over in OC pre menopausal users and a
greater physical performances in patients who used OC up than 10 years.
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Background
Osteoporosis in women following menopause is a major
health problem that leads to a high incidence of spine and
hip fractures. Many risk factors contribute to its develop-
ment and it is now well recognized that a chronically
hypoestrogenic state increases bone turnover that, in turn,
causes a critical decrease in bone mineral density (BMD),
an important determinant of fracture risk. Bone loss fol-
lowing menopause can be prevented or reduced by
replacement hormonal therapy.
Considerable controversy exists, however, as to whether
Oral contraceptives (Ocs) possess positive influences on
bone. Ocs have been reported to be a protective agent
against low BMD in several studies [1-4], but there are also
conflicting results [5,6]. In a review article Kuohung [7]
could not find any consensus on whether or not Ocs use
had a protective effect on BMD and bone metabolism.
Regarding the premenopausal women, there are although
a relatively few cross-sectional studies of OC use and BMD
have focused on premenopausal women. The Canadian
multicenter osteoporosis study found lower BMD values
in spine and trochanter in premenopausal women who
had used Ocs compared with those who have never used
Ocs [8]. A large study in a selected population of premen-
opausal Finnish women showed a small positive correla-
tion between OC use and age adjusted DXA
measurements [9]. These conflicting findings may be due
in large part the oestrogen/progestin doses in the OC
preparations, the duration of the studies and anatomic
sites evaluated.
On the other hand, previous research examining the influ-
ence of oral contraceptive use on muscle function has
been limited as pill users have been used as a control
rather than an experimental group. Sarwar and al demon-
strated changes in strength, relaxation and fatigability in
human muscle during the menstrual cycle while there
were no changes in any parameter in the women taking
the OC [10]. Elliott et al suggested that oral contraceptive
use does not significantly affect muscle strength [11].
We proposed a cross sectional study of pre and post men-
opausal women assessing BMD, bone biochemical mark-
ers and physical performance among OC past users and
comparable women who have never use Ocs.
Methods
Design and subjects
We conducted a cross-sectional study of 210 women who
had used combined OC for at least 2 years and compared
them to 200 who had never used OC. Women selected for
the study were recruited from the city of Rabat, through
advertisements in local hospitals. Informed consent was
obtained from all subjects and the study was approved by
ethics committee of our university hospital. We excluded
from the study all patients with a history of: (1) taking
drugs known to influence bone metabolism in the past 2
years, such as vitamin D, calcium, corticosteroids,
bisphosphonates and hormone replacement therapy; (2)
musclo-skeletal, thyroid, parathyroid, adrenal, hepatic, or
renal disease; (3) malignancy; and (4) hysterectomy.
Data collection and measurements
Each patient completed a questionnaire on socio demo-
graphic parameters and osteoporosis risk factors includ-
ing section on obstetric and menstrual history.
Reproductive history included age at menarche, number
of pregnancies, duration of lactation and age at meno-
pause. Oral contraceptives use was documented by the age
at which a women initiated use, and the name and type of
each preparation with the period of its use.
Bone mineral density measurements (BMD)
Lumbar spine, trochanter, femoral neck and total hip
BMD were measured by dual-energy X-ray absorptiometry
with a Lunar prodigy densitometer. Daily quality control
was carried out by measurement of a Lunar phantom. At
the time of the study, phantom measurements showed
stable results. The phantom precision expressed as the
CV(%) was 0.08. Both T and Z scores were obtained. In
the T-score calculations, the manufacturer's ranges for
European reference population were used because of the
absence of a Moroccan data base.
Biochemical measurements
Morning fasting blood and random urine samples were
collected from every subject for the measurement of the
following parameters: serum calcium, phosphorus, albu-
min, creatinine, 25(OH) D, osteocalcin, and C-terminal
cross-linking telopeptide of type I collagen (CTX). Serum
calcium, phosphorus, creatinine and albumin were meas-
ured by automated standard laboratory methods. Serum
25(OH) D was measured by chemiluminescence (Liaison,
Diasorin). The intra- and interassay coefficients of varia-
tion (CVs) were 5% and 11%, respectively and the normal
range was 20-60 ng/ml. Osteocalcin and CTX were both
measured by immunochemoluminometric assay (Elecsys,
Roche diagnostics, Mannheim, Germany). Intra- and inte-
rassay variances were 5% and 7% and the normal range
were 15--46 ng/ml for osteocalcin, and 0.3 ng/ml-0.6 ng/
ml for CTX.
Physical Performance Measures
Three measures to assess physical performance were used:
timed get-up-and-go test, five-times-sit-to-stand test and
2.4 meters speed walk. Time was measured in seconds
with a stopwatch and rounded to the nearest hundredth
of a second.BMC Women's Health 2009, 9:31 http://www.biomedcentral.com/1472-6874/9/31
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Timed get-up-and-go test (TGUG)
Time taken to complete the test "Get-up-and-Go": the
subject rises from a chair, walks 3 meters, turns around,
returns to the chair, and sits down. The subject was
instructed to: "Sit with your back against the chair and
your arms on the arm rests. On the word 'go', stand
upright, then walk at your normal pace to the line on the
floor, turn around, return to the chair, and sit down." The
stopwatch was started on the word 'go' and stopped when
the subject returned to the starting position.
Five-times-sit-to-stand test (5 TSTS)
Participants were asked to stand up and sit down five
times as quickly as possible without the use of hands and
were timed from their initial sitting position to the final
standing position at the end of the fifth stand.
8-feet (2.4 meters) speed walk (8 FSW)
The women were instructed to walk as fast as they could
in their ordinary shoes for 2.4 meters. Participants used
the footwear they normally used. The distance was
marked on the floor with red tape and the participant
stood just behind the starting line before the test. A digital
stopwatch was started when the participant started to walk
and stopped when the first foot crossed the finishing line.
Statistical analysis
The primary analysis of this study compared women who
used Ocs up than 2 years with those who had never used
Ocs. We used the Student's T test for matched samples and
the  Khi-2 test for the analysis of qualitative variables.
Descriptive statistics are presented as means and standard
deviations (SDs) for continuous variables. The factors that
remained significant or had a strong association with the
biochemical markers, BMD or physical tests were tested
by multiple linear regression analysis to eliminate poten-
tially confounding factors (age, BMI, number of pregnan-
cies, age at menarche,25 OH Vit D, total calcium intake).
All analyses were performed using SPSS, version 10.0 for
Windows. Results with p values < 0.05 were considered
statistically significant.
Results
In Table 1 we summarize the distribution of demographic
and other characteristics of OC past users and the control
group. In the total study population (pre and post meno-
pausal), the mean duration of OC use was 7,7 ± 6 years
with a range of 2 to 30 years. OC past users were likely
than women who had never use contraception to be
younger (54,3 ± 7,7 years vs 57,2 ± 11,2 years p = 0,003).
The groups were similar in terms of BMI, daily calcium
intake and age at menarche. Both before and after adjust-
ment for covariates, pre and post menopausal women
Table 1: Demographic and anthropometric characteristics of Ocs users and nonusers
All patients
n = 410
Pre-menopausal women n = 92 Post menopausal women n = 318
Variables OC users
N = 210
Nonusers
n = 200
OC users
n = 43
Nonusers
n = 49
OC users
n = 167
Nonusers
n = 151
Age (years) 54.3 ± 7.7 57.2 ± 11.2* 45 ± 5 43.9 ± 6.3 56.7 ± 6.3 61.5 ± 8.8
BMI (kg/m2) 28 ± 4.5 28.5 ± 4.8 28.8 ± 3.9 27.2 ± 4.3 27.8 ± 4.6 28.8 ± 4.9
Age at menarche (years) 12.7 ± 1.8 12.6 ± 1.6 13.1 ± 1.6 12.4 ± 1.4 12.5 ± 1.8 12.6 ± 1.7
Number of pregnancies 4.4 ± 2.2 4.2 ± 3.5 3.6 ± 1.8 1.6 ± 1.4 4.6 ± 2.2 5 ± 3.5
Breast feeding duration (months) 29.9 ± 42.7 30 ± 42.9 17.5 ± 21.9 10.5 ± 12 33.1 ± 46 35.9 ± 47
Age of menopause (years) 46.5 ± 9.4 47 ± 6.8 - - 47.9 ± 4.9 47.3 ± 5.7
Daily calcium intake (mg/j) 695 ± 229 688 ± 226 730 ± 258 713.1 ± 204 686.9 ± 221 680.8 ± 233
Lumbar spine(g/cm2) 1.01 ± 0.17 0.99 ± 0.19 1.14 ± 0.13 1.11 ± 0.17 0.984 ± 0.16 0.964 ± 0.18
Femoral neck (g/cm2) 0.88 ± 0.13 0.88 ± 0.15 1 ± 0.13 0.9 ± 0.15 0.859 ± 0.12 0.852 ± 0.14
Word's triangle (g/cm2) 0.72 ± 0.16 0.71 ± 0.17 0.86 ± 0.13 0.81 ± 0.15 0.69 ± 0.15 0.68 ± 0.16
Trochanter
(g/cm2)
0.72 ± 0.12 0.71 ± 0.14 0.82 ± 0.1 0.77 ± 0.13 0.699 ± 0.11 0.693 ± 0.13
Total femur (g/cm2) 0.93 ± 0.14 0.91 ± 0.15 1.06 ± 0.1 1.01 ± 0.1 0.903 ± 0.13 0.884 ± 0.14
Calcium
(mg/dl)
96.4 ± 5.2 97 ± 4.8 95.4 ± 6.1 95.9 ± 3.9 96.9 ± 4.7 97.6 ± 5.27
Phosphatus
(mg/dl)
36.1 ± 4.9 35.5 ± 5 34.56 ± 5.13 34.08 ± 4.16 36.9 ± 4.7 36.4 ± 5.3
25 OH Vitamin D 18.8 ± 8.1 17.4 ± 7.9 20.2 ± 7.4 17.08 ± 7.8 17.7 ± 8.17 18.16 ± 8.46
Osteocalcin
(ng/ml)
21.4 ± 10 23.9 ± 14 15.5 ± 7.5 21.6 ± 9* 23.9 ± 10.4 25.4 ± 17.4
CTX
(ng/ml)
0.42 ± 0.2 0.46 ± 0.21 0.30 ± 0.11 0.41 ± 0.2* 0.47 ± 0.22 0.50 ± 0.29
*Significantly different from Oral contraception users. p < 0,005BMC Women's Health 2009, 9:31 http://www.biomedcentral.com/1472-6874/9/31
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using Ocs and comparisons women did not differ signifi-
cantly in mean BMD at the lumbar spine, Trochanter, fem-
oral neck and total femur (table 1). Duration of OC
exposure (< 2-4 years; 4-6 years; > 6 years) vs no hormonal
contraception did not alter this finding (result not
shown).
When analysing the whole population, biochemical
markers values were similar for Ocs past users and control
subjects: osteocalcin (21,4 ± 10 ng/ml vs 23,9 ± 14 ng/ml;
p = 0,1) and CTX: (0,42 ± 0,2 ng/ml vs 0,46 ± 0,2 ng/ml;
p = 0,1) respectively (table 1). However, when analysing
the subgroup of premenopausal women, there was a sta-
tistically significant difference between OC past users and
never-users in osteocalcin (15,5 ± 7 ng/ml vs 21,6 ± 9 ng/
ml; p = 0,003) and in CTX (0,30 ± 0,1 ng/ml vs 0,41 ± 0,2
ng/ml; p = 0,025). This difference persisted after adjust-
ment for the important variables relating to contraception
and biochemical markers: age, BMI, age at menarche and
number of pregnancies (table 2).
Association between oral contraception use and physical 
performances
A comparison of mean duration of the three physical per-
formance tests according to the use of OC is shown in fig-
ure 1. OC past users had a significant greater performance
than did the never users group. This difference persisted
after adjusting for age.
The crude and adjusted mean differences for the timed
get-up-and-go test, the 8-foot walk test and the sit-to-
stand test by quartile OC duration are shown in Table 3.
The never user group was use a reference. There was a sig-
nificant negative association between the Timed get-up-
and-go test and the use of OC more than 10 years in the
crude analysis (P: 0,002) and after control for demo-
graphic variables including age, menopausal status and 25
OH vitamin D level (P: 0,027). Similar results were
observed with the sit-to-stand test. In the adjusted analy-
sis, subjects who used OC more than 10 years were 1.84 s
quicker in the Timed get-up-and-go test and 1.9 s quicker
in the sit-to-stand test (both: P < 0,005) than were never
user subjects. For the 8-foot walk test, there was also a sig-
nificant negative relation with the use of OC up than 10
years, but after adjustment for age, menopause and 25 OH
vitamin D level the effect of OC on the 8FWt was substan-
tially diminished and no longer achieved statistical signif-
icance.
Discussion
The findings of this cross-sectional study of pre and post
menopausal women suggest no evidence of a significant
difference in BMD between the contraceptive past users
and never user control groups. This result is in agreement
with some studies that have found no effects of OC on
BMD [5,12]. Available data on the effect of OC on BMD
are contradictory: Some previous studies found a positive
[1-4] association between BMD and the use of OC,
whereas others observed a lack of association [7,13]. The
apparently divergent findings from these previous studies
could be attributed to the wide range of ages studied, the
Table 2: Relationship between oral contraception use and 
biochemical bone markers in linear regression analysis
CTX Osteocalcin
β P β SD p
Age 0,15 ± 0,23 0,5 0,01 0,01 0,09
BMI -0,18 ± 0,31 0,5 0,002 0,01 0,7
Age at menarche 0,91 ± 0,80 0,2 0,02 0,02 0,3
Number of pregnancies 0,33 ± 0,68 0,6 0,002 0,02 0,8
Oral Contraception -7,71 ± 2,80 0,01 -0,12 0,06 0,03
Comparison of mean duration of the three physical perform- ance tests Figure 1
Comparison of mean duration of the three physical 
performance tests.
Table 3: Relationship between physical test and oral 
contraception duration use.
Univariabl analysis Multivariabl analysis*
β (CI 95) β (CI 95)
Timed get-up-and-go test
Never user 0 (reference) 0 (reference)
OC use < 3 y -1.39 (-3.31, 0.62) -0.89 (-2.7,0.9)
OC use for 3-6 y 0.04 (-2.13, 2.22) -0.45 (-2.5, 1.6)
OC 6-10 years 0.42 (-1.98, 2.83) -0.32 (-2.5, 1.8)
OC > 10 years -2.52 (-4.15,-0.93) -1.84 (-3.2,-0.47)
Five-times-sit-to-stand test
Never user 0 (reference) 0 (reference)
OC < 3 years -1.39 (-3.30, 0.50) -1.62 (-4,0.7)
OC 3-6 years 0.41 (-1.67, 2.49) 0.79 (-1.8, 3.4)
OC 6-10 years -0.54 (-2.84, 1.87) 0.34 (-2.4, 3.1)
OC > 10 years -1.56 (-3.10, -0.04) -1.9 (-3.6, -0.17)
8-feet (2.4 meters) speed walk
Never user 0 (reference) 0 (reference)
OC < 3 years -0.42 (-1.21, 0.37) 0.07 (-0.7,0.9)
OC 3-6 years -0.21 (-1.07, 0.65) -0.59 (-1.5, 0.3)
OC 6-10 years -0.014 (-0.97, 0.94) -0.3 (-1.3, 0.7)
OC > 10 years -0.85 (-1.50, -0.22) -0.22 (-1.3,-0.7)
* adjustment on age, menopausal status and 25 OH Vit D.BMC Women's Health 2009, 9:31 http://www.biomedcentral.com/1472-6874/9/31
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duration of the studies and the dosage of Ocs. Indeed,
Horsman and al reported that postmenopausal women
taking doses of oestrogen (EE) between 15 and 25 mg
daily experienced no bone loss, whereas those taking
doses of > 25 mg daily demonstrated net gain of bone
[14]. Thus, improved bone mineralization among low-
dose OC users is biologically plausible. Furthermore, con-
flicting finding may be due in large part to the longer
duration of OC use. Berenson and al reported that long-
term use of oral contraceptives increased bone mass [15].
This fact was supported by some studies showing that the
high-dose OC use for more than 10 years had the greatest
protection against low BMD [16,17]. Nevertheless, Petitti
reported that oral contraceptives had only short-term
effect in increasing BMD and this effect was reversible
[12]. But the mechanism involved in reversing a hormo-
nally initiated loss of BMD is not clear. In our study, the
nature and the exact dosage of Ocs used was not known.
But in the 1960s, when the women of our study needed
contraception, the oestrogen content of Ocs has always
been 50 ug ethinyl estradiol or less. Furthermore, longer
duration of OC use didn't show any influence on BMD.
Cross-sectional and prospective previous investigation of
biochemical markers of bone turnover in adult OC users
has produced findings consistent with those in our study
of decreased bone turnover. Garnero and al examined sev-
eral biochemical markers, including BSAP and DPD in a
cross-sectional comparison of users and nonusers of Ocs
[18]. When compared to the nonusers, the markers of
bone formation in the OC users decreased 15--24% and
bone resorption decreased 17--28%. Utilizing a prospec-
tive design, Karlsson and al reported a 50% decrease in
osteocalcin in OC users after 3 months [19]. In our study,
bone turn over markers (osteocalcin and CTX) were
decreased in premenopausal women who used OC com-
pared with none users while there was no change in post
menopausal women.
The effects of OC on muscle mass and performance have
been less well investigated. Exogenous, synthetic repro-
ductive hormones (in particular HRT) have been shown
to increase strength [20,21]. Therefore strength might
have been expected to increase as a result of oral contra-
ceptive administration. However, there are conflicting
data regarding the effect of OC on physical performances,
which may be due partly to differences in the treatment
combinations of oestrogen and progestin. OC use has
been shown to decrease, maintain, or have no effect on a
variety of strength measures [22-25]. In the present study,
patients who used oral contraceptive up than 10 years had
better physical performances than non users. Despite
adjustment for major confounding factors, the result did
not fluctuate. However, this effect of OC on physical per-
formance should be viewed with caution, as we are not
aware of any literature at present that finds the same
results.
Our study has many limitations. First, it was a cross sec-
tional study which the information was limited to past use
and wholly based on the subjects' recall instead of medi-
cal records and no information on type of Ocs was availa-
ble. Secondly, although the overall sample size was
adequate, the number of subjects in premenopausal
women was small, that may could reduced our power to
detect small differences in BMD.
However, this study had a number of strengths. First, the
study consisted of a large sample size. Second, we evalu-
ated three criteria in the same study; bone mineral den-
sity, biochemical markers of bone turnover and physical
performance with the use of a variety of validated test
measures. Finally, all variables were analyzed in two dis-
tinct groups: pre and post menopausal women.
Conclusion
In conclusion, the finding of this cross-sectional study of
pre and post menopausal women show no evidence of a
significant difference in BMD between Ocs users and
never user control groups, a decrease in bone turn over in
OC pre menopausal users and a greater physical perform-
ances in patients who used OC up than 10 years. Future
research should investigate the effect of oral contraceptive
use on other strength and performance based parameters
(such as muscle fatigability/endurance trials) and various
health measures so that specific recommendations can be
made to the pill user.
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